GLP-1 With Insurance 2026: Prior Auth, Step Therapy, Wins

Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.

Last updated: May 20, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~11 min read

Most major commercial insurers — Aetna, BCBS, Cigna, and UnitedHealthcare — cover Wegovy and Zepbound in 2026 with prior authorization. Typical requirements: BMI 30+ (or 27+ with comorbidity) plus documented lifestyle modification. Combined with manufacturer savings cards, copays drop to about $25/mo. CVS Caremark requires a Wegovy-first pathway for Zepbound. Medicare’s new GLP-1 Bridge Program launches July 1, 2026, covering Wegovy and Zepbound KwikPen only.

The 2026 Commercial Coverage Landscape

Five years into the modern GLP-1 era, commercial insurance has converged on a recognizable playbook: cover the drug, but gate it with prior authorization (PA), BMI thresholds, and increasingly step therapy. The May 2026 landscape is more navigable than it was in 2023 — most major employers now include at least one GLP-1 on formulary — but the rules differ enough by PBM that “I have insurance” is no longer a sufficient answer to “will it be covered?”

The PBM is what matters most. Your insurer (Aetna, BCBS, Cigna, UHC) sets the broad benefit. The PBM (CVS Caremark, Express Scripts, OptumRx) determines the formulary, the PA criteria, and whether step therapy is required. A patient with Aetna whose employer uses CVS Caremark as PBM faces different rules than one whose employer uses Express Scripts.

Aetna: Standard BMI Threshold, Modest Documentation

Aetna’s commercial PA for Wegovy and Zepbound is among the more navigable. The required criteria are typically:

• BMI 30 or higher, OR BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, OSA, or cardiovascular disease).
• Documentation of at least 6 months of lifestyle modification (diet, exercise, behavioral counseling). A signed attestation from your prescriber usually satisfies this.
• Age 18+.
• No personal/family history of MTC or MEN 2.

Approval is typically returned within 5-7 business days. Renewal at 6 months requires documented weight loss of at least 5% to continue coverage.

Cigna: Watch for the Step-Therapy Trap

Cigna’s PA criteria are broadly similar to Aetna’s, but many Cigna employer plans require step therapy through Contrave (naltrexone-bupropion) or phentermine before a GLP-1 is approved. Step-therapy requirements typically demand:

• A documented trial of Contrave (usually 3 months) showing less than 5% weight loss, OR
• Documented intolerance, contraindication, or failure of the cheaper alternative.

If your prescriber can document a clinical contraindication to Contrave (history of seizures, eating disorder, MAO inhibitor use, etc.), step therapy can be bypassed. If not, expect to spend the first 3 months on a non-GLP-1 first.

[provider=”ro”]

BCBS: 34 Affiliates, 34 Different Stories

Blue Cross Blue Shield is a federation of 34 independent affiliates, each setting its own formulary. The Federal Employee Program (FEP) and BCBS Massachusetts tend to be the most generous, covering both Wegovy and Zepbound without step therapy. Several southern affiliates (Alabama, Mississippi) have tighter PA criteria or exclude obesity coverage on certain employer plans.

The practical guidance: log into your member portal, search the drug formulary tool for “Wegovy” and “Zepbound,” and review the PA criteria PDF for your specific plan. If you can’t find clear formulary language, call the member services number on your card and ask: “Is Wegovy on formulary? Is Zepbound on formulary? Is step therapy required?”

UnitedHealthcare: Some Plans Limit to OSA

UHC plans through OptumRx vary by employer group. Some plans cover Wegovy and Zepbound on standard BMI criteria; others restrict GLP-1 coverage to obstructive sleep apnea (Zepbound’s 2024 OSA indication) or cardiovascular risk reduction (Wegovy’s 2024 cardiovascular indication). If your plan is OSA-restricted, your prescriber will need a sleep study documenting moderate-to-severe OSA before PA goes through.

The CVS Caremark Formulary Shift

The biggest commercial formulary change of the past 12 months is CVS Caremark’s decision to remove Zepbound from many of its commercial formularies in favor of a Wegovy-first pathway. The practical effect for patients with CVS Caremark as PBM:

• Wegovy is the preferred GLP-1 — PA is generally smoother.
• Zepbound is available only via formulary exception (often called “Wegovy-first” or “step-through Wegovy”) — patients must document either: (a) a 12-16 week trial of Wegovy with less than 5% weight loss, OR (b) clinically significant intolerance to Wegovy (severe persistent nausea, vomiting, gallbladder events, etc.).
• Patients already established on Zepbound at the time of the formulary change typically received grandfathered coverage for one renewal cycle, then must transition.

If you have a strong clinical reason to prefer Zepbound (better tolerability, OSA indication, prior failure of semaglutide), your prescriber can submit a formulary exception with supporting documentation. Approval rates on first submission are roughly 50-65% based on early 2026 PA data.

What Documentation Actually Wins a Prior Auth

Prior auth is a documentation exercise. The cleaner the file, the higher the first-pass approval rate. The five elements that consistently swing PAs:

1. Current BMI calculation from a measured height and weight (not patient-reported) in the EHR within the past 90 days.
2. Diagnosis code: ICD-10 E66.01 (morbid obesity, BMI 40+), E66.811 (BMI 35-39.9), or E66.9 (unspecified obesity) plus comorbidity codes.
3. Comorbidity documentation: labs (A1c, lipid panel), BP readings, sleep study, or prior cardiovascular event — whatever supports the comorbidity claim.
4. Lifestyle modification history: a chart note documenting 3-6 months of attempted diet, exercise, or behavioral program. Specific is better than generic — “12-week Noom enrollment from Jan-Mar 2026” beats “patient reports trying diets.”
5. Prior medication history: any prior weight-loss medication trials, especially if step therapy is in play.

Manufacturer Savings Cards: $25/Month Reality

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer commercial savings cards that stack on top of insurance:

• Wegovy savings card: $25/month copay when insurance covers Wegovy. Maximum annual benefit applies. Not available to Medicare, Medicaid, or other government-insured patients.
• Zepbound savings card: As low as $25/month with commercial insurance covering Zepbound. Annual cap roughly $6,019 in patient out-of-pocket savings. Same government-program exclusion.

Without insurance coverage, the same savings cards offer modest discounts off cash list price but the net cost is much higher — for those scenarios, see our cash-pay GLP-1 guide.

Step Therapy: What It Means and How to Fight It

Step therapy requires you to “step through” a cheaper or preferred medication before the insurer approves a more expensive alternative. For GLP-1s, the common step-through requirements are:

• Contrave (naltrexone-bupropion): 12 weeks, less than 5% weight loss documented.
• Phentermine: 8-12 weeks, less than 5% loss or intolerance.
• Saxenda (liraglutide): rarely required in 2026 (Wegovy has displaced it).
• Wegovy (for Zepbound applicants on CVS Caremark): 12-16 weeks.

Step therapy can be bypassed via:

1. Documented contraindication to the step-through drug (history of seizures bypasses Contrave; cardiovascular risk bypasses phentermine).
2. Documented prior failure at any prior employer/insurer — bring the records.
3. Formal exception request with peer-to-peer review by your prescriber.
4. State step-therapy override laws — over 30 states have laws requiring expedited override when documentation supports it.

Medicare GLP-1 Bridge Program: Launches July 1, 2026

The most significant 2026 development for Medicare beneficiaries: the GLP-1 Bridge Program launches July 1, 2026. Historically Medicare Part D has excluded coverage of medications used for weight loss under the Medicare Modernization Act. The Bridge Program creates a carve-out for obesity treatment.

What’s covered:

• Wegovy — all forms: standard pen (0.25-2.4mg), HD 7.2mg pen, and the oral pill formulation.
• Zepbound KwikPen ONLY: the multi-dose pen formulation. Single-dose vials are EXCLUDED.

What’s NOT covered:

• Zepbound single-dose vials (the LillyDirect self-pay vial program).
• Mounjaro for obesity (still T2D-only under Part D).
• Compounded semaglutide or tirzepatide.
• Saxenda, Contrave, phentermine (existing coverage rules apply).

Eligibility:

• Medicare Part D enrollment.
• BMI 30+, or 27+ with a qualifying comorbidity (cardiovascular disease, T2D, OSA, hypertension).
• Prior auth and step therapy may still apply depending on Part D plan sponsor.

Manufacturer savings cards do NOT stack with Medicare under federal anti-kickback rules, so out-of-pocket costs under the Bridge Program depend entirely on the Part D plan’s tier structure. Expect $30-$150/month in copay or coinsurance for most plans, with the donut hole still in play.

State Medicaid: Coverage Varies Wildly

Medicaid coverage for GLP-1s for obesity is set state-by-state, and the patchwork is dramatic in 2026:

• States covering Wegovy for obesity (selected): California (Medi-Cal), Pennsylvania, Virginia, Michigan, Delaware, Rhode Island, Massachusetts, Minnesota, and Tennessee (TennCare, since August 1, 2025). Connecticut ended its GLP-1 weight-loss coverage on July 31, 2025.
• States with limited or no obesity coverage: Texas, Florida, Georgia, Alabama, Mississippi, South Carolina, Tennessee, Louisiana, Arkansas, Oklahoma.
• T2D coverage is broader: nearly every state Medicaid covers Ozempic and Mounjaro for type 2 diabetes when prescribed for that indication.

For the current state-by-state picture — including the recent reversals in Connecticut (HUSKY Health) and Tennessee (TennCare) and the weight-loss-only exclusion in Colorado — see our Medicaid GLP-1 coverage by state guide.

If you’re Medicaid-eligible and live in a non-covering state, the practical paths are: (a) request a medical necessity exception based on documented cardiovascular or OSA indication; (b) explore manufacturer patient assistance programs (Novo Nordisk PAP and Lilly Cares); or (c) consider self-pay options through NovoCare or LillyDirect. See our no-insurance GLP-1 guide for the cash-pay landscape.

[provider=”mochi-health”]

When PA Is Denied: Appeals That Actually Work

Roughly 25-35% of first-submission GLP-1 PAs are denied. Of those, an estimated 40-60% are overturned on appeal when documentation is solid. The appeal hierarchy:

1. Internal appeal: resubmit with corrected/expanded documentation. Most insurers respond within 30 days.
2. Peer-to-peer review: your prescriber speaks directly with the insurer’s medical reviewer. This is the highest-yield step — providers report 60-75% success rates when they have time to make the call.
3. External review: if internal appeals fail, federal law (ACA) guarantees access to independent external review for medical-necessity denials.
4. State insurance commissioner complaint: the last formal step if external review fails.

Documenting impact on cardiovascular risk (Wegovy has FDA approval for cardiovascular risk reduction in obese patients with established CVD) is one of the strongest appeal arguments — for more on that pathway, see our GLP-1 cardiovascular benefits guide.

Telehealth Providers That Handle PA For You

If the documentation and appeals burden feels overwhelming, several telehealth providers handle the entire PA process in-house:

• Sequence / WeightWatchers Clinic: dedicated insurance navigation team. Files PA, handles step therapy, manages appeals. Brand-name only — no compounded options. Membership $25/mo intro then $74/mo.
• Ro: Wegovy and Zepbound partner. In-house PA support for both. Membership ~$135/mo plus medication.
• Teladoc Health: integrated with most employer health plans. Generally insurance-route for both Wegovy and Zepbound.

Compare full pricing and coverage logistics in our best GLP-1 telehealth comparison and the head-to-head Wegovy vs Zepbound cost guide. The full provider matrix lives at our weight-loss provider hub.

Frequently Asked Questions

Sources

• NovoCare Wegovy savings card eligibility (verified May 2026)
• Lilly Zepbound pricing and savings information (verified May 2026)
• Zepbound prior-authorization clinical criteria reference (verified May 2026)
• CMS GLP-1 Bridge Program implementation notice (effective July 1, 2026)
• CVS Caremark commercial formulary update Q4 2025 (Wegovy-first pathway)
• State Medicaid drug rebate program data — Kaiser Family Foundation analysis (2026)

Medical disclaimer: Information here is educational only. Insurance coverage rules change frequently and vary by employer, plan year, and state. Verify your specific plan’s formulary and PA criteria directly with your insurer before relying on the above. GLP-1 medications can cause serious side effects including pancreatitis, gallbladder disease, and thyroid C-cell tumors (boxed warning). Consult a licensed clinician before starting, switching, or stopping any prescription weight-loss medication.